A RANDOMIZED PHASE II TRIAL OF EPOCH (AIDS)

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 在国家癌症研究所进行的试点试验中，在超过75%的新诊断的艾滋病相关淋巴瘤患者中，使用EPOCH(依托泊苷、泼尼松、长春新碱、环磷酰胺、羟道诺霉素(多诺阿比星))的输注化疗与持久完全缓解有关。这项试验的目的是确定在新诊断的艾滋病相关B细胞淋巴瘤患者的治疗中，在EPOCH方案中加入单抗利妥昔单抗是否会提高完全缓解率和耐受性。在这项由NCI-AIDS恶性肿瘤联盟赞助的多中心试验中，70名患者将随机接受利妥昔单抗治疗，要么与EPOCH同时服用，要么作为维持治疗。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. In pilot trials conducted at the National Cancer Institute, infusional chemotherapy with EPOCH (etoposide, prednisone, Oncovin, cyclophosphamide, hydroxydaunomycin (doroxubicin) is associated with durable complete remission in over 75% of patients with newly diagnosed AIDS-related lymphomas. The purpose of this trial is to determine if the addition of the monoclonal antibody rituximab to the EPOCH regimen will improve the complete remission rate and its durability in the treatment of newly diagnosed patients with AIDS-related B-cell lymphomas. In this multi-center trial sponsored by the NCI-AIDS Malignancy consortium, 70 patients will be randomized to receive either rituximab either given concurrently with ePOCH or as maintenance therapy.